Cargando…

Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials

Artemisinin and its derivatives have shown broad-spectrum antitumor activities in vitro and in vivo. Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities. However, some problems such as poor solubility, toxicity and cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Cangcang, Zhang, Huihui, Mu, Lingli, Yang, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573816/
https://www.ncbi.nlm.nih.gov/pubmed/33117153
http://dx.doi.org/10.3389/fphar.2020.529881
_version_ 1783597516896337920
author Xu, Cangcang
Zhang, Huihui
Mu, Lingli
Yang, Xiaoping
author_facet Xu, Cangcang
Zhang, Huihui
Mu, Lingli
Yang, Xiaoping
author_sort Xu, Cangcang
collection PubMed
description Artemisinin and its derivatives have shown broad-spectrum antitumor activities in vitro and in vivo. Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities. However, some problems such as poor solubility, toxicity and controversial mechanisms of action hamper their use as effective antitumor agents in the clinic. In order to accelerate the use of ARTs in the clinic, researchers have recently developed novel therapeutic approaches including developing novel derivatives, manufacturing novel nano-formulations, and combining ARTs with other drugs for cancer therapy. The related mechanisms of action were explored. This review describes ARTs used to induce non-apoptotic cell death containing oncosis, autophagy, and ferroptosis. Moreover, it highlights the ARTs-caused effects on cancer metabolism, immunosuppression and cancer stem cells and discusses clinical trials of ARTs used to treat cancer. The review provides additional insight into the molecular mechanism of action of ARTs and their considerable clinical potential.
format Online
Article
Text
id pubmed-7573816
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75738162020-10-27 Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials Xu, Cangcang Zhang, Huihui Mu, Lingli Yang, Xiaoping Front Pharmacol Pharmacology Artemisinin and its derivatives have shown broad-spectrum antitumor activities in vitro and in vivo. Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities. However, some problems such as poor solubility, toxicity and controversial mechanisms of action hamper their use as effective antitumor agents in the clinic. In order to accelerate the use of ARTs in the clinic, researchers have recently developed novel therapeutic approaches including developing novel derivatives, manufacturing novel nano-formulations, and combining ARTs with other drugs for cancer therapy. The related mechanisms of action were explored. This review describes ARTs used to induce non-apoptotic cell death containing oncosis, autophagy, and ferroptosis. Moreover, it highlights the ARTs-caused effects on cancer metabolism, immunosuppression and cancer stem cells and discusses clinical trials of ARTs used to treat cancer. The review provides additional insight into the molecular mechanism of action of ARTs and their considerable clinical potential. Frontiers Media S.A. 2020-10-06 /pmc/articles/PMC7573816/ /pubmed/33117153 http://dx.doi.org/10.3389/fphar.2020.529881 Text en Copyright © 2020 Xu, Zhang, Mu and Yang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xu, Cangcang
Zhang, Huihui
Mu, Lingli
Yang, Xiaoping
Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials
title Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials
title_full Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials
title_fullStr Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials
title_full_unstemmed Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials
title_short Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials
title_sort artemisinins as anticancer drugs: novel therapeutic approaches, molecular mechanisms, and clinical trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573816/
https://www.ncbi.nlm.nih.gov/pubmed/33117153
http://dx.doi.org/10.3389/fphar.2020.529881
work_keys_str_mv AT xucangcang artemisininsasanticancerdrugsnoveltherapeuticapproachesmolecularmechanismsandclinicaltrials
AT zhanghuihui artemisininsasanticancerdrugsnoveltherapeuticapproachesmolecularmechanismsandclinicaltrials
AT mulingli artemisininsasanticancerdrugsnoveltherapeuticapproachesmolecularmechanismsandclinicaltrials
AT yangxiaoping artemisininsasanticancerdrugsnoveltherapeuticapproachesmolecularmechanismsandclinicaltrials